Efficacy Over Time of LHRH Analogs in the Treatment of PCa-A Prospective Analysis Using Serum Testosterone to Determine Dosing Intervals

Urology

Volumn 73, Issue 3, 2009, Pages 631-634

  Greil, S ^a   Robinson, E A ^a   Singal, B ^a   Kleer, E ^a  

^a Section of Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN DERIVATIVE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; COST CONTROL; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; HORMONAL REGULATION; HUMAN; INJECTION; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MALE; PATIENT IDENTIFICATION; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TECHNIQUE; TESTOSTERONE BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG MONITORING; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 60549103530     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.08.516     Document Type: Article

References (9)

1. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant dosing study considerations. J Urol 160 (1998) 1685-1688
2. Oefelein M.G. Serum testosterone-based luteinizing hormone-releasing hormone agonist redoing schedule for chronic androgen ablation: a phase I assessment. Urology 54 (1999) 649-699
3. Oefelein M.G. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing agonists in patients with prostate cancer. J Urol 169 (2003) 251-255
4. Pathak A.S., Pacificar J.S., Shapiro C.E., et al. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol 177 (2007) 2132-2135
5. Nejat R.J., Rashid H.H., Bagiella E., et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
6. Walsh P.C. Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2 (1975) 25-28
7. Bayoumi A.M. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92 (2000) 1731-1739
8. Calais Da Silva F.M., Calais Da Silva F., Bono A., et al. Phase III intermittent MAB vs continuous MAB. J Clin Oncol 24 (2006) 220-227
9. Oefelein M.G., and Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (2000) 726-729